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Low immunogenicity predicted for
emerging avian-origin H7N9
Implication for influenza vaccine design
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A new avian-origin influenza virus emerged near Shanghai in February 2013, and by the beginning of May it had
caused over 130 human infections and 36 deaths. Human-to-human transmission of avian-origin H7N9 influenza
A has been limited to a few family clusters, but the high mortality rate (27%) associated with human infection has
raised concern about the potential for this virus to become a significant human pathogen. European, American,
and Asian vaccine companies have already initiated the process of cloning H7 antigens such as hemagglutinin
(HA) into standardized vaccine production vehicles. Unfortunately, previous H7 HA-containing vaccines have been
poorly immunogenic. We used well-established immunoinformatics tools to analyze the H7N9 protein sequences
and compare their T cell epitope content to other circulating influenza A strains as a means of estimating the
immunogenic potential of the new influenza antigen. We found that the HA proteins derived from closely related
human-derived H7N9 strains contain fewer T cell epitopes than other recently circulating strains of influenza, and
that conservation of T cell epitopes with other strains of influenza was very limited. Here, we provide a detailed
accounting of the type and location of T cell epitopes contained in H7N9 and their conservation in other H7 and
circulating (A/California/07/2009, A/Victoria/361/2011, and A/Texas/50/2012) influenza A strains. Based on this analysis, avian-origin H7N9 2013 appears to be a “stealth” virus, capable of evading human cellular and humoral immune
response. Should H7N9 develop pandemic potential, this analysis predicts that novel strategies for improving vaccine immunogenicity for this unique low-immunogenicity strain of avian-origin influenza will be urgently needed.

Introduction
Between February and May 2013, avian-origin H7N9 emerged
as a significant cause of human morbidity and mortality in
China, with pandemic potential. As of May 2013, the new influenza virus has caused more than 130 infected patients in China
to seek hospital care, of which 27% have died and many remain
hospitalized.1,2 Infections are sporadic, usually associated with
exposure to birds such as chickens and pigeons, and the extent of
human-to-human transmission appears to be very low at present.
Sampling methods may not be entirely accurate since viral titers
are low in upper respiratory samples, thus some cases of asymptomatic infection and transmission may have been missed.3
Despite the fact that human-to-human transmission seems
to be rare, the ongoing outbreak of H7N9 influenza is of great
concern to infectious disease experts for four important reasons.
First, individual cases of nearly identical H7N9 virus infections
have been identified in a wide range of locations within China
in a very short period of time, which strongly suggests that the
virus is already widespread in an as-yet-unidentified reservoir

population.4 Second, an H7 subtype influenza has never before
infected humans to any extent, meaning the human population
has little or no immunity, which could lead to a very high mortality rate.5 H7N9 infection has led to death in approximately 27%
of reported cases, and many infected patients are still hospitalized
in serious condition.2 Third, viral sequences suggest the possibility of resistance to certain antiviral medications, rendering some
current treatments ineffective.1,6 And fourth, viral isolates bear
hemagglutinin receptor binding site mutations that better enable
this avian virus to infect mammals, and only a few additional
mutations might be needed for full adaptation for human-tohuman transmission.6
The source of the viral infections appears to be contact with
poultry in the majority of cases. Despite these reports, approximately 40% of patients have had no contact with birds of any
type.7 Furthermore, the number of infections among chickens in
market-based samples is very low, an observation that has puzzled
epidemiologists. Despite these reports of low infection rates, the
genomic sequences of the virus suggests that the H7N9 sequence
is closest to poultry-origin H7 viruses,3 and as a result of this
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Figure 1. The rapid emergence of H7N9 in several locations in China reflects wide-spread distribution in the animal population and potential for even
greater spread. H7N9 is a virus that deserves serious consideration. Should a traveler get infected in China, flight routes from the outbreak regions would
quickly carry any human-transmissible virus to huge population centers in Europe, North America and Asia. An estimated 70% of the world population resides within two hours’ travel time of destination airports (calculated using gridded population-density maps and a data set of global travel
times, map supplied by A. J. Tatem, Z. Huang and S. I. Hay (2013). Unpublished data. (A.J.T., University of Southampton, UK; Z.H., University of Florida,
Gainesville; S.I.H., University of Oxford, UK.) Reprinted by permission from Macmillan Publishers Ltd: Nature News 2013.9

association, a mass culling of the poultry population has been
implemented in Shanghai, Nanjing, and other regions across
China.33
Alarmingly, human H7N9 cases have already spread
outside of China; a business man who had traveled to one of
the affected provinces was recently hospitalized in Taiwan and
remains in serious condition as of May.8 According to experts
cited by Nature, 70% of the global population outside of China
lives within two hours of an airport linked to the outbreak
regions by either a direct flight or a single connection (Fig. 1).9
Consequently, should genetic changes occur that permit facile
human-to-human transmission, the H7N9 outbreak will rapidly
become a global pandemic.
Analysis of H1N1 (2009) demonstrated cross-conservation
of T cell epitopes. The current H7N9 outbreak is somewhat
reminiscent of March 2009, when pandemic H1N1 (A/
California/07/2009) emerged in Mexico. At that time, CDC
studies showed that most individuals lacked pre-existing humoral
immunity that was cross-protective against the pandemic
strain (A/California/07/2009), and that vaccination with the
2008/2009 seasonal trivalent influenza vaccine (TIV) containing
H1N1 A/Brisbane/59/2007 rarely elicited neutralizing antibody
responses against 2009 H1N1 isolates.10,11 Despite this concern,
during the course of the 2009 pandemic, the new H1N1 was
not associated with significant morbidity or mortality among
older adults, a population normally at high risk for complications
following seasonal influenza infection.12,13
At that time, the importance of T cell epitope responses to
cross-protective immunity (against different strains of influenza) was already well established. Accordingly, we proposed
that cross-reactive T memory responses with prior H1N1 viruses
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might protect against severe H1N1 disease, despite the absence
of cross-reactive humoral immunity, and we published T cell
epitopes in the hemagglutinin (HA) and neuraminidase (NA)
proteins that were predicted by immunoinformatic analysis to be
cross-conserved with HA and NA sequences present in the trivalent inactivated influenza vaccine administered that season.14
This hypothesis was later validated in animal and human studies,
and the impact of the H1N1 pandemic was, in fact, much less
severe than had been expected. The lack of B cell epitope crossreactivity did not appear to lead to high morbidity and mortality
rates during the pandemic.
Unfortunately, our prediction is very different for H7N9: we
find (1) very low T cell epitope content in the HA sequences,
and (2) very poor potential for cross-reactivity with T cells
specific for currently circulating influenza strains. Coupled with
the absence of any prior exposure to H7 in human populations
(meaning established humoral immunity may be entirely absent),
these findings suggest that the H7N9 influenza virus, should it
acquire the ability to be transmitted from person to person, has
the potential to have a much more serious impact on human
populations than did pandemic H1N1 influenza in 2009.
Application of in silico analysis to H7N9 demonstrates low
T cell epitope content. Employing the EpiMatrix immunoinformatics suite, we compared the protein sequences of emerging
H7N9 strains to the sequences of other recent strains of influenza
and previous H7 strains. We also provide a detailed analysis of
the T cell epitopes (both class I cytotoxic T cell epitopes and class
II T helper epitopes) in the H7N9 strains. We find: (1) HA from
the 2013 outbreak H7N9 and a wide range of avian H7 strains
have low immunogenic potential (based on T cell epitope analysis, as previously published)15 when compared with HA from
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vaccines.19,20 Other low-immunogenicity proteins
that score in the negative range on this immunogenicity scale include albumin, transferrin, and the
immunoglobulin G Fc domain, observations that
have been previously published by our group.21
HLA class II cluster analysis. We have published our approach to finding highly immunogenic epitopes that are ‘promiscuous’ and highly
conserved in multiple strains of the same pathogen.22 We call this approach the ‘immunogenic
consensus sequence (ICS) approach.’ In our own
work, we have found that these clustered epitopes
are the most effective ones to include in vaccines to
promote antibody response and vaccine efficacy.23
Accordingly, we derived a total of 101 ICS epitopes
for H7N9, containing multiple 9-mer frames predicted to bind to many HLA alleles and conserved
in a minimum of three of the four human-derived
Figure 2. Potential immunogenicity of emerging influenza A (H7N9) HA and HA from
avian-origin H7N9 sequences (Table 1). ICS were
the current seasonal vaccine and H7 vaccines. The number of HLA ligands (putative T
derived from among all 11 H7N9 antigens. Of the
cell epitopes) per unit protein is plotted on an Immunogenicity Scale. This scale is cor101 ICS class II epitopes, 16 were found to contain
related with observed immunogenicity in retrospective and prospective studies.16,17 The
9-mer sequences that were previously published as
numbers used in this scale reflect the difference between the number of predicted T cell
epitopes we would expect to find in a protein of any given size by chance alone (based
T cell epitopes or class II MHC binders. None of
on an evaluation of more than 10,000 random protein sequences) and the number of
these 16 published 9-mers have been identified in
putative epitopes predicted by the EpiMatrix System for a given protein. The EpiMatrix
the H7N9 influenza surface HA and NA antigens,
Protein Score of an “average” protein is zero. EpiMatrix Protein Scores above zero indibut rather all are found in internal proteins: six in
cate the presence of excess MHC ligands and denote a higher potential for immunoM1, eight in NP, and two in PB1 (see ‘Published in
genicity, while scores below zero indicate the presence of fewer potential HLA ligands
than expected and a lower potential for immunogenicity. H7 has fewer HLA ligands than
IEDB’ column, Table 1).
expected, which is reflected in its negative immunogenicity score. Seasonal strains of
Next we checked for conservation among cirinfluenza are scored for potential immunogenicity on the left; their scores are much
culating strains of influenza and vaccine backbone
higher than H7N9.
proteins. In this case, we considered all epitopes
sharing at least 80% amino acid similarity as
seasonal influenza strains that are known to be immunogenic; defined by Kesmir et al. “conserved”.34 Only 11 promiscuous T
(2) H7-HA conservation analysis suggests limited potential for cell epitopes were found in H7N9-HA, and only four of these are
T cell epitope cross reactivity with previously and currently cir- somewhat cross-conserved in other strains. In contrast, we found
culating seasonal strains; and (3) T cell epitopes that have cross- 16 promiscuous helper T cell epitopes in the 2009 H1N1-HA
reactive potential are found among internal proteins. A full T sequence, of which nine (56%) were 100% conserved in the
cell epitope analysis for novel avian H7N9 and a list of cross- 2008–2009 influenza vaccine strain; 81% were either identical or
conserved epitopes is compiled in this report. This prediction of had one conservative amino acid substitution. Thus the emerglow immunogenic potential and poor epitope conservation has ing H7N9 is predicted to be less immunogenic, based on our
important implications for the development of effective H7N9 analysis, and is also shown to be less conserved in other influenza
vaccines.
strains. Table S1 provides detailed information on the H7N9
class II clustered (promiscuous) epitopes, their conservation in
Results
other influenza strains, and information on published epitopes if
cross conservation is present.
Overall HLA class II epitope content. The immunogenicCross reactivity—class II. As shown in Table 1, a total of
ity potential score of H7N9 antigens was derived by summing 96 of the 101 putative epitopes are conserved in other H7N9
EpiMatrix scores over the entire protein and normalizing for strains. Of the 11 putative H7-HA epitopes, only four have
protein length. Immunogenicity potential has been directly minimal cross-reactivity to the current 2012–2013 TIV; three
correlated with antibody titers in several published studies.16,18 are found in A/Victoria/361/2011 (H3N2), one was found in
The immunogenicity score for H7N9 HA is remarkably low A/California/7/2009 (H1N1), and no conserved sequences
(Fig. 2): H7-HA scores -8.11, well below the expectation for a were identified in B/Wisconsin/1/2010. Greater homology
random sequence, and also significantly below the scores of with H3-HA is expected, as H7 and H3 are group 2 influenza
H1-HA (+18.22) and H3-HA (+14.30). The current H7 also A viruses whereas H1 is a group 1 virus. Similarly, only one of
scores within the same range as other H7-HA strains, some of the six N9-NA putative epitopes was found to be conserved in
which were part of poorly immunogenic monovalent inactivated the current TIV, with 86% similarity to the 2012–2013 vaccine
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2013–2014 vaccine
recommendations

Other H7N9

Vaccine backbone

Published

2012–2013 vaccine strains

HA

11

0

10

1

3

2

3

M1

9

6

9

9

9

9

9

9

9

2

2

H7N9
Ag
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Putative epitopes

Table 1. Numbers of putative class II ICS constructed from the four emerging avian H7N9 strains and numbers of those epitopes conserved (at least 80%
amino acid similarity) in recently circulating and vaccine backbone influenza strains

A/California/
7/2009
(H1N1)

A/Victoria/
361/2011
(H3N2)

A/Christchurch/
16/2010
(H1N1)

A/Texas/
50/2012
(H3N2)

M2

2

0

2

2

2

2

2

NA

6

0

5

0

1

0

1

TIV

LAIV

A/Puerto Rico/
8/34 (H1N1)

A/Ann Arbor/7/67
(H2N2)

NEP

6

0

5

6

6

--

6

6

6

NP

11

8

11

9*

11

--

11

11

11

NS1

3

0

2

3

3

--

3

3

3

PA

14

0

14

14

14

--

14

14

14

PB1

18

2

17

18

18

--

18

18

18

PB1-F2

1

0

1

--

0

--

0

1

1

PB2

20

0

20

20

20

--

20

20

20

Counts of published epitopes from IEDB mapped to H7N9 ICS are shown in the third column. Table values marked with ‘--‘ represent an antigen (Ag) that
was unavailable for download. It can be easily seen that peptides from HA and NA are less conserved among other strains than epitopes derived from the
internal proteins. *A/California/7/2009 NP sequence accessed from GISAID was truncated and did not cover C-terminal NP ICS.

strain A/Victoria/361/2011 (H3N2) as well as the 2013–2014
vaccine recommendation A/Texas/50/2012 (H3N2). Conversely,
83 of the 84 putative epitopes derived from internal H7N9 proteins are conserved in at least one of the currently circulating
influenza A strains. Fourteen H7N9 ICS derived from internal
proteins are conserved in influenza B/Wisconsin/1/2010; high
conservation of internal antigen epitopes is consistent in vaccine
backbone strains. Still, previously circulating strains of influenza
had more T cell epitopes than were found in the current H7N9.
Epitope content—class I. As shown in Table 2, a total
of 1,242 putative class I epitopes were found by EpiMatrix,
spanning the 11 H7N9 antigens across the six supertype class I
alleles. Of those 1,242 sequences, a total of 48 were found to be
identified as either published T cell epitopes or MHC binders.
None of these 48 included epitopes from the external HA and
NA antigens; instead, the epitopes conserved with published
epitopes were found in the M1 (17), NP (9), NS1 (1), PA (6),
and PB1 (15) proteins, as shown in Table 2. Table S2 provides
detailed information on the H7N9 epitopes, their conservation
in other influenza strains, and information on published epitopes
if cross-conservation is present.
Cross reactivity—class I. A total of 967 (77.9%) of the
1,242 putative epitopes were found to be > 90% conserved in
other H7N9 strains. Only 4/150 and 1/146 HA and NA class
I putative epitopes, respectively, were found to be conserved in
the current 2012–2013 TIV, which is not surprising since this
is an entirely new strain of influenza for the human population.
A similar trend of low conservation can be seen when H7N9 is
compared with the LAIV backbone strain and the strains recommended for 2013–2014 vaccination. A total of 609 of the remaining 946 putative class I epitopes, spanning the internal proteins,
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were found to be conserved in one or more of the circulating
2012–2013 influenza A strains. Similar conservation trends can
be seen when comparing the epitopes derived from internal antigens to the LAIV backbone strain and the strains recommended
for 2013–2014 vaccination.
The above analysis is based on in silico predictions using a
well-validated immunoinformatics toolkit.24 Based on historical
performance, we expect these epitope predictions to be 93-99%
accurate; in addition, correlations with published H1N1 and
H3N2 epitopes are provided in Tables S1 and S2. Our findings
suggest that overall H7-HA immunogenicity will be poor, and
that immune responses to H7N9 will be driven by T cell epitopes
found in the internal proteins. Given the poor immunogenicity of
previous H7 vaccines,25 whole attenuated or inactivated vaccines
containing a greater number of T cell epitopes in their internal
proteins (or subunit vaccines that incorporate conserved internal
protein T cell epitopes) may be more effective immunogens than
subunit HA/NA for H7N9.
Discussion
In 2009, we performed a similar analysis of H1N1, following emergence of the H1N1 2009 virus. Using EpiMatrix, a
T cell epitope prediction and comparison tool, we compared
the sequences of the three HA and NA proteins contained in
2008–2009 TIV to their counterparts in A/California/04/2009
(H1N1), looking for cross-conserved T cell epitope sequences. We
found > 50% conservation of T helper and cytotoxic T lymphocyte (CTL) epitopes between novel swine-origin influenza virus
and TIV HA for selected HLA.14 At that time, we suggested that
seasonal influenza vaccination or infection might protect against
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Table 2. Numbers of putative class I epitopes discovered in four emerging avian H7N9 strains and numbers of those epitopes conserved (at least 80%
amino acid similarity) in recently circulating and vaccine backbone influenza strains

H7N9 Ag

Putative epitopes

Published

Other H7N9

2013/2014 vaccine
recommendations

HA

150

0

122

2

2

2

2

M1

89

17

52

55

45

55

45

53

45

M2

53

0

38

26

22

26

22

21

19

NA

146

0

130

1

1

1

1

NEP

53

1

45

12

20

–

20

26

30

NP

146

8

126

59*

59

–

60

77

67

NS1

91

1

32

18

15

–

15

27

21

2012/2013 vaccine strains

A/California/
7/2009 (H1N1)

A/Victoria/
361/2011 (H3N2)

A/Christchurch/
16/2010 (H1N1)

A/Texas/
50/2012
(H3N2)

Vaccine backbone
TIV

LAIV

A/Puerto Rico/
8/34 (H1N1)

A/Ann Arbor/7/67
(H2N2)

PA

150

6

130

115

103

–

104

118

109

PB1

150

15

137

111

115

–

115

111

123

PB1-F2

64

0

15

–

0

–

0

3

4

PB2

150

0

140

123

90

–

90

103

110

Counts of published epitopes from IEDB mapped to H7N9 epitopes discovered here are shown in the third column. Table values marked with ‘–‘ represent
an antigen (Ag) that was unavailable for download. Epitope sequences from HA and NA are less conserved among other strains than epitopes derived from
the internal proteins. *A/California/7/2009 NP sequence accessed from GISAID was truncated and did not cover C-terminal NP ICS.

pandemic H1N1. We then extended the analysis to define
core T cell epitopes in H1N1 2009, and to define the extent
of cross-reactivity between the pandemic virus and the 20092010 seasonal H1N1 vaccine strain, A/Brisbane/59/2007. The
2009 H1-HA protein contained 16 class II (T helper) peptide
sequences that were both highly conserved between the pandemic and A/Brisbane/59/2007 H1N1 strains and likely to be
presented in the context of multiple HLA alleles.14 Schanen et
al. (VaxDesign), in collaboration with EpiVax, then confirmed
that human influenza-specific T helper cells from donors not
previously exposed to H1N1 2009 were capable of generating cross-reactive effector responses against the 2009 H1N1
virus.26 These studies helped support the hypothesis that existing influenza-specific CD4 + T cells generated cross-protective
cellular responses that limited disease severity and virus spread
in individuals lacking cross-reactive humoral immunity, and
was substantiated by subsequent animal studies demonstrating
that seasonal H1N1 exposure protected ferrets27 and mice (Ted
Ross, unpublished) from disease in pandemic H1N1 infection.
Our previous study contradicted predictions that H1N1 would
cause serious illness in human populations. Even though H1N1
spread rapidly (presumably due to the absence of any memory B
cell response), hospitalizations were limited to younger individuals and pregnant women who might have had limited prior exposure to influenza and absent T memory responses.
The lack of antibody response to the 2009 H1N1 is similar
to the situation with the current H7N9, but from the T cell perspective, the two are markedly different. If H7N9 becomes easily
transmissible between humans, widespread transmission (due to
the absence of memory B cell responses and antibody that might

954

protect against H7, which has never circulated in human populations) and widespread illness (due to the absence of cross-reactive T cell potential) are probable. The mortality rate following
establishment of H7N9 disease is greater than 27%; thus concern
about the potential for this virus to cause significant morbidity
and mortality in human populations, should the virus adapt to
spread from human to human, are entirely justified.
In addition, due to the poor predicted immunogenicity of
H7N9, inactivated vaccines based on the H7-HA and N9-NA
antigens, whether produced in eggs or mammalian cells, are
likely to be poorly immunogenic based on the analysis described
here. Previous studies of influenza vaccines have clearly demonstrated the link between T cell response and antibody titers,28
thus the absence of T helper epitopes in the HA antigen of the
current circulating strain of H7N9 can be expected to lead to
very poor immunogenicity, particularly for subunit vaccines
containing HA alone. New strategies that will improve protection against H7N9 are needed, as the virus has the potential to
become a worldwide threat.
Alternative vaccine approaches for H7N9 would include: (1)
addition of adjuvants to boost immune responses against the
weaker T cell epitopes; (2) addition of cross-conserved epitopes
to the HA in a subunit vaccine (as proposed by our team to
NIAID); (3) enhancement of the HA with cross-conserved epitopes (a vaccine design currently under production at EpiVax); (4)
development of T cell vaccines for influenza that contain all of
the most immunogenic T cell epitopes derived from H7, including those that are cross conserved with H7N9 (a DNA-string-of
beads design is currently in production); and (5) use of two doses
of vaccine rather than one.
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In contrast with 2009 H1N1, 2013 H7N9 is a significant
concern for global health. As described above, H7N9 has
fewer epitopes than would normally occur in a random protein
sequence. As this virus has not, by current reports, circulated in
humans previously, it is unclear why the virus would evolve to
have fewer T cell epitopes than predicted. Those T cell epitopes
that we predict might be of use for vaccine design are included
in the supplemental tables (Tables S1 and S2) as a service to the
influenza vaccine development community. Whether ‘evolutionary’ in nature or not, we postulate that the relative paucity of
T cell epitopes (both novel and conserved) in the key antigens
of emerging H7N9 will have serious consequences for human
immune response and vaccine design.
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Materials and Methods
Sequence collection. Four human H7N9 influenza sequences
were downloaded from GISAID (http://platform.gisaid.org/).
The downloaded sequences were from A/Hangzhou/1/2013, A/
Anhui/1/2013, A/Shanghai/1/2013, and A/Shanghai/2/2013.
The 25 remaining non-human H7N9 strains available on
GISAID were also downloaded to confirm if epitopes found
within the four human-sourced strains were conserved in H7N9
as a whole, which would indicate functional dependency and low
probability of mutation. The novel H7N9 sequences analyzed
were selected from sequences that were available on GISAID
on April 6th, 2013. Three additional influenza strains found in
the current 2012–2013 TIV [A/California/07/2009(H1N1), A/
Victoria/361/2011(H3N2), and B/Wisconsin/01/2010] were also
downloaded for evaluation of conservation and cross-protection
with EpiMatrix-identified H7N9 T cell epitopes.
The following accessions were utilized for epitope crossconservation analysis: A/California/7/2009 (H1N1): GISAID
EPI_ISL_77637; A/Victoria/361/2011 (H3N2): GISAID EPI_
ISL_134450; B/Wisconsin/01/2010: GISAID EPI_ISL_115174;
A/Christchurch/16/2010 (H1N1): GISAID EPI_ISL_79722;
A/Texas/50/2012 (H3N2): GISAID EPI_ISL_136503; A/Ann
Arbor/7/1967 (H2N2): GISAID EPI_ISL_130404; A/Puerto
Rico/8/34 (H1N1): Genbank AAM75164.1; AAM75162.1;
AAM75610.1; AAM75158.1; AAM75156.1; AAM75163.1;
AAM75161.1; AAM75159.1; AAM75157.1; AAM75155.1;
ADX99593.1.
Conservatrix. The Conservatrix algorithm29 was employed to
parse and compare 9-mers and 10-mers (class I analysis only) for
highly conserved segments among the four human H7N9 influenza sequences, organized by protein of origin: HA, M1, M2,
NA, NEP, NP, NS1, PA, PB1, PB1-F2, or PB2. Highly conserved

www.landesbioscience.com

epitope sequences were then analyzed for putative binding to eight
common HLA class II (DRB1*0101, DRB1*0301, DRB1*0401,
DRB1*0701,
DRB1*0801,
DRB1*1101,
DRB1*1301,
DRB1*1501) and six common HLA class I alleles (A0101, A0201,
A0301, A2402, B0702, and B4403).
EpiMatrix. Using the EpiMatrix algorithm,30 epitopes were
selected from the output of highly conserved epitopes produced
by Conservatrix. Each amino acid was scored for predicted
affinity to eight common HLA class II and six common HLA
class I alleles, covering > 90% of the human population.31
EpiAssembler. Sets of overlapping, conserved, and
immunogenic class II epitopes were identified and assembled
into extended immunogenic consensus sequences (ICS) with
the EpiAssembler32 tool. Processing and presentation of these
sequences would allow for presentation of the highly conserved
peptides in the context of more than one class II MHC. The
resulting peptide is not a “pseudo-sequence” as such, since each
constituent epitope occurs in its corresponding position in the
native protein but in different variants of the pathogen. These
epitopes are of high value for vaccine design as they are both
promiscuous and highly conserved.
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